|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
DE69532127T2
(de)
*
|
1994-07-20 |
2004-08-26 |
Genetics Institute, Inc., Cambridge |
Interaktions-fullensysteme zum nachweis von protein-interaktionen
|
|
NZ306767A
(en)
|
1995-04-11 |
2000-03-27 |
Univ Johns Hopkins |
Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
|
|
CA2252886C
(en)
*
|
1996-04-26 |
2008-02-12 |
Massachusetts Institute Of Technology |
Three-hybrid screening assay
|
|
DE29724617U1
(de)
*
|
1996-04-26 |
2002-06-13 |
Massachusetts Institute Of Technology, Cambridge, Mass. |
Drei-Hybrid-Kit zur Molekülauswahl
|
|
US5776689A
(en)
*
|
1996-07-19 |
1998-07-07 |
The Regents Of The University Of California |
Protein recruitment system
|
|
US5807708A
(en)
*
|
1996-07-30 |
1998-09-15 |
Millennium Pharmaceuticals, Inc. |
Conservin nucleic acid molecules and compositions
|
|
US5846722A
(en)
*
|
1996-10-16 |
1998-12-08 |
Terrapin Technologies, Inc. |
System to detect small molecule/peptide interaction
|
|
US6365347B1
(en)
*
|
1997-04-11 |
2002-04-02 |
The Regents Of The University Of California |
Method for identifying disruptors of biological pathways using genetic selection
|
|
WO1999028502A1
(en)
*
|
1997-11-28 |
1999-06-10 |
Invitrogen Corporation |
Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
|
|
EP1035207A1
(de)
*
|
1999-03-09 |
2000-09-13 |
MultiGene Biotech GmbH |
cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
|
|
WO2000061746A1
(en)
|
1999-04-12 |
2000-10-19 |
Agensys, Inc. |
13 transmembrane protein expressed in prostate cancer
|
|
EP1792989A1
(de)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
|
|
WO2001000866A1
(en)
*
|
1999-06-26 |
2001-01-04 |
Odyssey Pharmaceuticals, Inc. |
An in vivo library-versus-library selection of optimized protein-protein interactions
|
|
PT1200590E
(pt)
|
1999-08-12 |
2009-03-24 |
Agensys Inc |
Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
|
|
HK1048494B
(en)
|
1999-10-05 |
2009-06-12 |
Agensys, Inc. |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
|
US6893818B1
(en)
*
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
|
US20030211495A1
(en)
*
|
2000-03-08 |
2003-11-13 |
Richard Hopkins |
Reverse n-hybrid screening method
|
|
DK1299727T3
(da)
|
2000-07-12 |
2009-06-15 |
Agensys Inc |
Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
|
|
CA2705366A1
(en)
|
2000-08-28 |
2002-03-07 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
|
|
JP5165175B2
(ja)
*
|
2000-09-11 |
2013-03-21 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Muc1細胞外ドメインおよびそれから得られた癌治療組成物
|
|
US7312325B2
(en)
*
|
2000-09-26 |
2007-12-25 |
Duke University |
RNA aptamers and methods for identifying the same
|
|
EP1531842A4
(de)
*
|
2000-12-22 |
2007-03-07 |
Dana Farber Cancer Inst Inc |
Regulation des zellwachstums durch muc1
|
|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
|
ATE497603T1
(de)
|
2001-03-02 |
2011-02-15 |
Gpc Biotech Ag |
Drei-hybrid-assaysystem
|
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
WO2002083921A2
(en)
|
2001-04-10 |
2002-10-24 |
Agensys, Inc. |
Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
DK2070939T3
(da)
*
|
2001-05-25 |
2014-06-23 |
Univ Duke |
Modulatorer af farmakologiske midler
|
|
EP2287186B1
(de)
|
2001-09-06 |
2014-12-31 |
Agensys, Inc. |
Nucleinsäure und entsprechendes Protein, STEAP-1, bei der Behandlung und zum Nachweis von Krebs
|
|
US20040049024A1
(en)
*
|
2001-12-07 |
2004-03-11 |
Geoff Clark |
Compositions and methods related to the minn1 tumor suppressor gene and protein
|
|
US20040086945A1
(en)
*
|
2002-06-03 |
2004-05-06 |
The Procter & Gamble Company |
Hairless protein-interacting partner complexes and methods thereto
|
|
WO2004003150A2
(en)
*
|
2002-06-26 |
2004-01-08 |
Yale University |
Modulators and modulation of the interacton between rgm and neogenin
|
|
AU2003243151A1
(en)
|
2002-08-16 |
2004-03-03 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
|
US20060099713A1
(en)
*
|
2002-10-01 |
2006-05-11 |
Buck Institute |
Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
|
|
JP2007524361A
(ja)
|
2003-02-10 |
2007-08-30 |
アジェンシス, インコーポレイテッド |
膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質
|
|
WO2004092339A2
(en)
*
|
2003-04-11 |
2004-10-28 |
Ilex Products, Inc. |
Modulation of muc1 mediated signal transduction
|
|
CA2526274C
(en)
|
2003-05-30 |
2015-12-01 |
Agensys, Inc. |
Prostate stem cell antigen (psca) variants and subsequences thereof
|
|
GB0315248D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Hoffmann La Roche |
HCV regulated protein expression
|
|
WO2005042573A1
(en)
|
2003-10-24 |
2005-05-12 |
Dana-Farber Cancer Institute, Inc. |
Modulation of the interaction of muc1 with muc1 ligands
|
|
DE602004020855D1
(de)
*
|
2003-11-20 |
2009-06-10 |
Hoffmann La Roche |
Spezifische Marker für Stoffwechselssyndrome
|
|
JP2007523214A
(ja)
*
|
2004-02-23 |
2007-08-16 |
ジェンザイム コーポレイション |
デスレセプターリガンド誘導アポトーシスのmuc1アンタゴニスト増強方法
|
|
EP2460811A1
(de)
*
|
2004-04-22 |
2012-06-06 |
Regado Biosciences, Inc. |
Verbesserte Modulatoren von Gerinnungsfaktoren
|
|
NZ551627A
(en)
|
2004-05-28 |
2010-02-26 |
Agensys Inc |
Antibodies and related molecules that bind to PSCA proteins
|
|
US8034553B2
(en)
|
2004-06-24 |
2011-10-11 |
Kimberly-Clark Worldwide, Inc. |
Biomarkers for wound healing
|
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
WO2008025564A2
(en)
|
2006-08-31 |
2008-03-06 |
Nexigen Gmbh |
Methods for detecting protein-peptide interactions
|
|
EP1927364A1
(de)
|
2006-12-01 |
2008-06-04 |
Ecole Normale Superieure De Lyon |
Polypetitde mit modulatorischer Wirkung auf Zellen
|
|
WO2008097844A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Dana -Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
|
|
US7972870B2
(en)
|
2007-02-02 |
2011-07-05 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
|
|
EP2034020A1
(de)
*
|
2007-08-30 |
2009-03-11 |
Procomcure Biotech GmbH |
Verfahren zur Herstellung eines modifizierten Peptids
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2101173A1
(de)
*
|
2008-03-14 |
2009-09-16 |
Vivalis |
In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist
|
|
WO2009138933A1
(en)
*
|
2008-05-15 |
2009-11-19 |
Koninklijke Philips Electronics N.V. |
Method and system for generating an x-ray bean
|
|
JP2013507950A
(ja)
|
2009-10-22 |
2013-03-07 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク |
グアニン交換因子インヒビター及び抗癌剤としてのその使用
|
|
MX2012006560A
(es)
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
|
WO2011083147A1
(en)
|
2010-01-08 |
2011-07-14 |
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh |
Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
|
|
WO2011131626A1
(en)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
EP3369746A1
(de)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
WO2016105542A2
(en)
|
2014-12-24 |
2016-06-30 |
Neximmune, Inc |
Nanoparticle compositions and methods for immunotherapy
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
CN108883150A
(zh)
|
2015-11-19 |
2018-11-23 |
阿斯克雷佩西治疗公司 |
具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
|
|
CN116769054A
(zh)
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
EP3426278B1
(de)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Einzeldomänenantikörper gegen cd20
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
EP3455245A2
(de)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutisches targeting von nichtzellulären strukturen
|
|
MX2019003895A
(es)
|
2016-10-04 |
2019-10-07 |
Asclepix Therapeutics Inc |
Compuestos y metodos para activar la señalizacion tie2.
|
|
WO2018077893A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
EP3661536A4
(de)
|
2017-08-03 |
2021-07-21 |
Asclepix Therapeutics, Inc. |
Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
|
|
WO2019075056A1
(en)
|
2017-10-10 |
2019-04-18 |
The Johns Hopkins University |
BIODEGRADABLE BIOMIMETIC PARTICLES
|
|
GB2584211B
(en)
*
|
2017-11-16 |
2023-05-24 |
Synthex Inc |
Selective modulation of protein-protein interactions
|
|
EP3743448A4
(de)
|
2018-01-26 |
2021-11-03 |
Orionis Biosciences, Inc. |
Xcr1-bindende wirkstoffe und verwendungen davon
|
|
KR102877915B1
(ko)
|
2018-02-05 |
2025-10-29 |
오리오니스 바이오사이언시즈 인코포레이티드 |
섬유아세포 결합제 및 이의 용도
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
|
MA54955A
(fr)
|
2019-02-15 |
2021-12-22 |
Integral Molecular Inc |
Anticorps anti-claudine 6 et leurs utilisations
|
|
JP7773372B2
(ja)
|
2019-03-28 |
2025-11-19 |
オリオニス バイオサイエンシズ,インコーポレイテッド |
線維芽細胞活性化タンパク質結合物質およびその使用
|
|
EP3969592A4
(de)
|
2019-05-15 |
2023-01-04 |
Synthex, Inc. |
Selektiver abbau von proteinen
|
|
EP4069731A4
(de)
|
2019-12-03 |
2024-05-29 |
Alamar Biosciences, Inc. |
Nukleinsäure-gekoppelter immun-sandwich-assay (nulisa)
|
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
|
GB202009710D0
(en)
*
|
2020-06-25 |
2020-08-12 |
Univ Bath |
Cross-linking methods
|
|
US20220267450A1
(en)
|
2020-10-14 |
2022-08-25 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
EP4384219A4
(de)
|
2021-08-10 |
2025-06-18 |
Viridian Therapeutics, Inc. |
Zusammensetzungen, dosen und verfahren zur behandlung von schilddrüsenaugenkrankheit
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液-脳脊髄液関門通過抗体
|
|
US20240228620A1
(en)
|
2022-10-06 |
2024-07-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
TW202430574A
(zh)
|
2022-11-30 |
2024-08-01 |
美商積分分子股份有限公司 |
針對密連蛋白6之抗體,包括其雙特異性格式
|
|
AU2024243709A1
(en)
|
2023-04-03 |
2025-11-06 |
Katholieke Universiteit Leuven |
Blood-brain barrier crossing antibodies
|
|
AU2024287547A1
(en)
|
2023-07-07 |
2026-01-22 |
Viridian Therapeutics, Inc. |
Methods of treating chronic thyroid eye disease
|
|
AU2024299328A1
(en)
|
2023-07-21 |
2026-01-22 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
WO2025136985A1
(en)
|
2023-12-17 |
2025-06-26 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫受體抑制蛋白及相關方法
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2026019692A2
(en)
|
2024-07-15 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory fusion proteins and related methods
|